Do you have myositis and have served in the military?
The goal of this research study is to compare persons who developed myositis during active duty to military personnel without autoimmune or muscle diseases, to assess risk factors for myositis. Compensation is provided for participants.
The study is run by physicians at the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, U.S. Department of Health and Human Services.
Frederick W. Miller, M.D., Ph.D. oversees researchers in his group as well as others in national and international consortia that evaluate and conduct a wide range of basic and clinical studies on adult and juvenile autoimmune diseases. His interests are broad and he wishes to understand what triggers these diseases and how to best assess, treat, cure and ultimately prevent them. He obtained his M.D. and Ph.D. from Case Western Reserve University, went on to medical residencies at Emory and Stanford, and then did rheumatology and immunology training at the NIH. His work in the field of autoimmune diseases spans over three decades and involves many aspects of the phenotypes, environmental risk factors, epidemiology, immunology, genetics, pathogenesis, evaluation and treatment of immune-mediated diseases. He has focused much of his work on autoimmune muscle diseases.
Adam Schiffenbauer, M.D. is an Associate Research Physician in the Environmental Autoimmunity Group, and an adult rheumatologist with an expertise in myositis. He received his B.A. from The University of Chicago and his M.D. from Pennsylvania State University. He completed an internal medicine residency at George Washington University, and his fellowship in rheumatology at the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD. He then joined Dr. Frederick Miller’s group in NIEHS in Bethesda, MD. Dr. Schiffenbauer’s work has been focused on environmental and genetic risk factors, phenotypes, pathogenesis, advanced imaging, evaluation, and therapeutic trials in myositis.